By showing that silencing ATP6V1E1 markedly reduces the proliferative capacity of HCC cells, these results support the rationale for developing ATP6V1E1 inhibitors as potential therapeutic agents. Here, ATP6V1E1 is linked to hepatocellular carcinoma.